Proactive drug safety surveillance should be at the heart of the new Health Data Research Service
BMJ · 13.05.2026 · 393 · s908
DOI: 10.1136/bmj.s908 ↗Kurz gefasst
Editorial in der Zeitschrift BMJ, online erschienen am 13.05.2026. Verfasst von Alison Cave und 1 weiteren Autor:innen. Beteiligte Einrichtung: Medicines and Healthcare products Regulatory Agency. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
The UK’s surveillance system is limited by data that are fragmented, difficult and slow to access, and of variable quality, write AnthonyHarnden and AlisonCave
Autor:innen und Institutionen
- Medicines and Healthcare products Regulatory Agency.
Zitieren
APA
Cave, A., & Harnden, A. (2026). Proactive drug safety surveillance should be at the heart of the new Health Data Research Service. BMJ, 393, s908. https://doi.org/10.1136/bmj.s908
Vancouver
Cave A, Harnden A. Proactive drug safety surveillance should be at the heart of the new Health Data Research Service. BMJ. 2026;393:s908. doi:10.1136/bmj.s908
BibTeX
@article{Cave2026,
author = {Cave, Alison and Harnden, Anthony},
title = {Proactive drug safety surveillance should be at the heart of the new Health Data Research Service},
journal = {BMJ},
year = {2026},
volume = {393},
pages = {s908},
doi = {10.1136/bmj.s908}
}
EUVIMED